Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting

Evolocumab has been shown to consistently reduce low-density lipoprotein cholesterol (LDL-C) across populations. The phase 3 studies included administration in the home-use and in-clinic settings but did not specifically evaluate the feasibility of home-use administration. Two clinical studies enrol...

Descripción completa

Detalles Bibliográficos
Autores principales: Dent, Ricardo, Joshi, Raju, Stephen Djedjos, C., Legg, Jason, Elliott, Mary, Geller, Michelle, Meyer, Dawn, Somaratne, Ransi, Recknor, Chris, Weiss, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783317/
https://www.ncbi.nlm.nih.gov/pubmed/27066336
http://dx.doi.org/10.1186/s40064-016-1892-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783317/
https://www.ncbi.nlm.nih.gov/pubmed/27066336
http://dx.doi.org/10.1186/s40064-016-1892-3

Ejemplares similares